148
Reynolds KK, Valdes R, Hartung BR, Linder LW. Individualizing warfarin therapy. Pers Med.
2007;4:11–31.
SEARCH Collaborative Group, Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-
induced myopathy – a genomewide study. N Engl J Med. 2008;359:789–99.
Shuldiner AR, O’Connell JR, Biden KP, et al. Association of cytochrome P450 2C19 genotype
with the antiplatelet effect and clinical effi cacy of clopidogrel therapy. JAMA. 2009;302:
849–57.
Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation,
bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent place-
ment. Circulation. 2010;121:512–8.
Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and
cardiovascular events. N Engl J Med. 2009;360:363–75.
Singer JB, Lewitzky S, Lero E, et al. A genome-wide study identifi es HLA alleles associated with
lumiracoxib-related liver injury. Nat Genet. 2010;42:711–4.
Sissung TM, Mross K, Steinberg SM, et al. Association of ABCB1 genotypes with paclitaxel-
mediated peripheral neuropathy and neutropenias. Eur J Cancer. 2006;42:2893–6.
Takeuchi F, McGinnis R, Bourgeois S, et al. A genome-wide association study confi rms VKORC1,
CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet.
2009;5:e1000433.
The International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with
clinical and pharmacogenetic data. N Engl J Med. 2009;360:753–64.
Thompson AJ, Newman WG, Elliott RA, et al. The cost-effectiveness of a pharmacogenetic test: a
trial-based evaluation of TPMT genotyping for azathioprine. Value Health. 2014;17:22–33.
Verbelen M, Collier DA, Cohen D, et al. Establishing the characteristics of an effective pharmaco-
genetic test for clozapine induced agranulocytosis. BioRxiv. 2014. doi: http://dx.doi.
org/10.1101/010900
4 Pharmacogenetics